This research investigates the application of mitotane, currently approved by the FDA for adrenocortical carcinoma treatment, as a potential anti-platelet drug targeting ischemic heart disease (IHD). This is because, IHD has been identified as a growing problem, and the current antiplatelet agents are always limited either by resistance or the risk of bleeding. Hence the quest for alternatives to these therapies. Antiplatelet drug repurposing was performed with a ligand-based approach that used computational structural comparison of these compounds with mitotane and clopidogrel bisulphate. DrugRep bake-off results indicated that mitotane has a binding score of 0.294 to the protein 4PY0, which suggest potential effects in platelet aggregation, but not related to the formation of clots. Docking studies revealed that mitotane formed significant contacts with several amino acids located in the docking site. The present study espouses the benefits of drug repurposing and encourages more clinical trials evaluation studies on the efficacy of mitotane in Ischemic Heart Disease Treatment.
Keywords: Mitotane, Drug Repurposing, Antiplatelet Agent, Ischemic Heart Disease, Clopidogrel, Platelet Aggregation, Computational Methods, Ligand-Based Screening, Drug Discovery, Cardiovascular Health
How to cite this article: Khot S, Bhosale N, Shaikh W, Daphal G, Changediya V, Udugade B, Repurposing of Mitotane an Anticancer Agent as Anti- Platelet Agent for Ischemic Heart Disease Treatment. Int J Drug Deliv Technol. 2025;15(4): 1741-1749, DOI: 10.25258/ijddt.15.4.25